BioCentury
ARTICLE | Top Story

ASCO focuses on value and cost

June 2, 2015 1:44 AM UTC

Value and costs of cancer care were dominant themes over the weekend at the American Society of Clinical Oncology meeting in Chicago, with five separate sessions on the topics, including alternative payment models to ASP plus 6% as well as presentations by ASCO on its forthcoming value framework and early data from Anthem Inc.'s cancer pathway program.

Oncologists are reimbursed for infused cancer drugs at the rate of ASP plus 6%, which incentivizes doctors to select higher-cost regimens when equally effective lower cost drugs are available. ...